Project Grant F30CA294612
Award Date
1/10/25
Completion Date
10/31/27
Dollars Obligated
$108K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This federal Project Grant award for $415,830, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring and detection of reliable biomarkers that represent treatment response and drug resistance in ovarian cancer.
The award will fund the development of the Nano-CRISPR system, which incorporates single extracellular vesicle (EV)...
This $275,000 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project objectives are to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ machine learning to...
This $326,103 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the key molecular mechanisms driving multicellular crosstalk within the ovarian tumor microenvironment. The University of Oklahoma Health Sciences Center, the awardee, will leverage gold nanoparticles as a tool to decipher the role of the protein IGFBP2 in mediating interactions between cancer cells, cancer-associated fibroblasts, and endothelial cells. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research by Rutgers University to investigate how dysfunctions in the cellular response to mitochondrial stress influence the progression of epithelial ovarian cancer and the orchestration of protective anti-tumor immunity. The $936,746 award, running from December 1, 2024 to November 30, 2029, will leverage the university's unique mouse models, reagents, and extensive ovarian...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
The National Cancer Institute (NCI) awarded Brigham & Women's Hospital a $178,989 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate the use of circulating microRNAs (miRNAs) as a biomarker for assessing ovarian cancer risk. The project aims to discover whether the serum miRNA profile associated with BRCA1/2 mutations can be generalized to identify other high-risk groups, such as those with mutations in other DNA repair genes or strong...
The National Cancer Institute awarded The Johns Hopkins University a $443,191 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop engineered biomimetic tumor invasion models for screening chemotherapeutic agents against breast cancer metastasis. The project leverages expertise in cancer molecular biology, tissue engineering, machine learning, and drug development to create 2D and 3D tumor models that mimic the extracellular matrix and collective...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $349,808 to Oncurie Inc. to continue development of their novel targeted radiopharmaceutical platform for imaging and therapy of ovarian cancer. The goal is to refine the molecular structure and formulation of the compound to improve scalability, handling, and radiolabeling efficiency. The compound leverages a folate receptor-binding moiety and Oncurie's...
This federal Project Grant award of $1,228,021.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting The Johns Hopkins University in advancing clinical research in ovarian cancer. The grant, awarded on June 1, 2024, will fund the university's efforts to conduct innovative scientific studies and clinical trials over a four-year performance period ending on May 31, 2028. This award enables Johns Hopkins to leverage its...
This $505,613 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of statistical and computational approaches to utilize genomic data for precision cancer prevention at the Fred Hutchinson Cancer Center.
The key objectives are to: (1) develop deep learning-based methods to identify tumor subtypes associated with poor outcomes and integrate external biomarker data to improve risk prediction; and (2)...